Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently developing an investigational drug for the treatment of lupus nephritis. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.